2020
Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination
Chuang YM, Dutta NK, Gordy JT, Campodónico VL, Pinn ML, Markham RB, Hung CF, Karakousis PC. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination. Frontiers In Immunology 2020, 11: 680. PMID: 32411131, PMCID: PMC7198710, DOI: 10.3389/fimmu.2020.00680.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, BacterialAntitubercular AgentsBacterial ProteinsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell LineChronic DiseaseDrug Resistance, BacterialFemaleGuanosine PentaphosphateGuinea PigsHydrolasesIsoniazidLigasesMacrophagesMiceMice, Inbred C57BLMycobacterium tuberculosisTreatment OutcomeTuberculosisTuberculosis VaccinesVaccinationVaccines, DNAConceptsTherapeutic vaccinationDNA vaccineT cellsC57BL/6 miceMtb persistersGuinea pigsAntigenic environmentFirst-line anti-TB drugsChronic TB infectionDrug-susceptible tuberculosisLung bacterial burdenAnti-TB drugsSpleens of miceHartley guinea pigsActivity of isoniazidAntitubercular treatmentReactive CD4Reactive CD8TB chemotherapyTB infectionTB treatmentCurrent regimenDaily dosesBacterial burdenIsoniazid treatment
2019
Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2Degludec
2000
In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy
Havlir D, Tierney C, Friedland G, Pollard R, Smeaton L, Sommadossi J, Fox L, Kessler H, Fife K, Richman D. In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy. The Journal Of Infectious Diseases 2000, 182: 321-325. PMID: 10882616, DOI: 10.1086/315683.Peer-Reviewed Original ResearchConceptsCD4 cell countD4TCell countD4T armD4T monotherapyWeeks of therapyHuman immunodeficiency virusCopies/mLGreater antiviral activityT monotherapyHIV RNACurrent regimenImmunodeficiency virusPharmacologic antagonismCombination therapyMean reductionZidovudineAntiviral activityVivo antagonismProgressive declinePatientsCells/DdIIntracellular levelsTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply